Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats

被引:112
作者
Fulgencio, JP [1 ]
Kohl, C [1 ]
Girard, J [1 ]
Pegorier, JP [1 ]
机构
[1] CNRS,CTR RECH ENDOCRINOL MOL & DEV,F-92190 MEUDON,FRANCE
关键词
D O I
10.2337/diabetes.45.11.1556
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of troglitazone and pioglitazone on glucose and fatty acid metabolism were studied in hepatocytes isolated from 24-h-starved rats. These thiazolidinediones inhibited long-chain fatty acid (oleate) oxidation and produced a very oxidized mitochondrial redox state. By contrast, thiazolidinediones did not affect the rate of medium-chain fatty acid (octanoate) oxidation or the activity of mitochondrial carnitine palmitoyltransferase (CPT) I. Thiazolidinediones inhibited selectively triglyceride synthesis but not phospholipid synthesis. The combined inhibition of oleate oxidation and esterification by troglitazone was due to a noncompetitive inhibition of mitochondrial and microsomal long-chain acyl-CoA synthetase (ACS) activities. It was suggested that troglitazone must be metabolized into its sulfo-conjugate derivative in liver cells to inhibit mitochondrial and microsomal ACS activities. Thiazolidinediones inhibited glucose production from lactate/pyruvate or from alanine. Analysis of gluconeogenic metabolite concentrations suggested that troglitazone would inhibit gluconeogenesis at the level of pyruvate carboxylase and glyceraldehyde-3-phosphate dehydrogenase reactions. It was concluded that 1) at a similar concentration, troglitazone was more efficient than pioglitazone to inhibit fatty acid metabolism and gluconeogenesis and 2) the inhibition of gluconeogenesis by troglitazone could be the result of the inhibition of long-chain fatty acid oxidation (decrease in acetyl-CoA, NADH-to-NAD(+), and ATP-to-ADP ratios).
引用
收藏
页码:1556 / 1562
页数:7
相关论文
共 38 条
  • [1] Bremer J., 1984, Fatty Acid Metabolism and its Regulation, V7, P113
  • [2] INVITRO STUDIES ON THE ACTION OF CS-045, A NEW ANTIDIABETIC AGENT
    CIARALDI, TP
    GILMORE, A
    OLEFSKY, JM
    GOLDBERG, M
    HEIDENREICH, KA
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (10): : 1056 - 1062
  • [3] REVIEW ISSUE - INTRODUCTION
    DEFRONZO, RA
    [J]. DIABETES CARE, 1992, 15 (03) : 317 - 317
  • [4] HEPATIC TRIGLYCERIDE HYDROLYSIS AND DEVELOPMENT OF KETOGENESIS IN RABBITS
    DUEE, PH
    PEGORIER, JP
    ELMANOUBI, L
    HERBIN, C
    KOHL, C
    GIRARD, J
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1985, 249 (05): : E478 - E484
  • [5] FERRE P, 1979, BIOCHEM J, V182, P593, DOI 10.1042/bj1820593
  • [6] CHARACTERIZATION OF CS-045, A NEW ORAL ANTIDIABETIC AGENT .2. EFFECTS ON GLYCEMIC CONTROL AND PANCREATIC-ISLET STRUCTURE AT A LATE STAGE OF THE DIABETIC SYNDROME IN C57BL/KSJ-DB/DB MICE
    FUJIWARA, T
    WADA, M
    FUKUDA, K
    FUKAMI, M
    YOSHIOKA, S
    YOSHIOKA, T
    HORIKOSHI, H
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (11): : 1213 - 1218
  • [7] SUPPRESSION OF HEPATIC GLUCONEOGENESIS IN LONG-TERM TROGLITAZONE TREATED DIABETIC KK AND C57BL/KSJ-DB/DB MICE
    FUJIWARA, T
    OKUNO, A
    YOSHIOKA, S
    HORIKOSHI, H
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (04): : 486 - 490
  • [8] METABOLIC EFFECTS OF SUPPRESSION OF NONESTERIFIED FATTY-ACID LEVELS WITH ACIPIMOX IN OBESE NIDDM SUBJECTS
    FULCHER, GR
    WALKER, M
    CATALANO, C
    AGIUS, L
    ALBERTI, KGMM
    [J]. DIABETES, 1992, 41 (11) : 1400 - 1408
  • [9] GIRARD J, 1995, DIABETES METAB, V21, P79
  • [10] GIRARD J, 1986, ISOLATED CULTURED HE, P87